These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19481687)

  • 1. Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditions.
    Raynaud JP; Augès M; Liorzou L; Turlier V; Lauze C
    Int J Pharm; 2009 Jun; 375(1-2):28-32. PubMed ID: 19481687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.
    Lefèvre G; Sedek G; Huang HL; Saltzman M; Rosenberg M; Kiese B; Fordham P
    J Clin Pharmacol; 2007 Apr; 47(4):471-8. PubMed ID: 17389556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men.
    Raynaud JP; Aumonier C; Gualano V; Betea D; Beckers A
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):177-84. PubMed ID: 18325758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adhesion testing of polyurethane matrix patches for transdermal delivery of testosterone.
    Dittgen M; Gansen P
    Pharmazie; 2012 Jun; 67(6):567-8. PubMed ID: 22822549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyurethanes as self adhesive matrix for the transdermal drug delivery of testosterone.
    Gansen P; Dittgen M
    Drug Dev Ind Pharm; 2012 May; 38(5):597-602. PubMed ID: 22010861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone patches for female sexual dysfunction.
    Drug Ther Bull; 2009 Mar; 47(3):30-4. PubMed ID: 19261838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems.
    Jordan WP
    Am J Contact Dermat; 1997 Jun; 8(2):108-13. PubMed ID: 9153333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioadhesive film for dermal and transdermal drug delivery.
    Padula C; Nicoli S; Aversa V; Colombo P; Falson F; Pirot F; Santi P
    Eur J Dermatol; 2007; 17(4):309-12. PubMed ID: 17540637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and evaluation of a monolithic drug-in-adhesive patch for testosterone based on styrene-isoprene-styrene block copolymer.
    Ma J; Wang C; Luo H; Zhu Z; Wu Y; Wang H
    J Pharm Sci; 2013 Jul; 102(7):2221-34. PubMed ID: 23650152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adhesive properties: a critical issue in transdermal patch development.
    Cilurzo F; Gennari CG; Minghetti P
    Expert Opin Drug Deliv; 2012 Jan; 9(1):33-45. PubMed ID: 22171789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of adhesive properties of transdermal therapeutic systems containing nitroglycerin.
    Minghetti P; Casiraghi A; Cilurzo F; Montanari L
    Boll Chim Farm; 2001; 140(2):63-7. PubMed ID: 11417388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasticizers in the manufacture of novel skin-bioadhesive patches.
    Gal A; Nussinovitch A
    Int J Pharm; 2009 Mar; 370(1-2):103-9. PubMed ID: 19073242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of the Sinomenine transdermal patch.
    Wang J; Ruan J; Zhang C; Ye Y; Cai Y; Wu Y
    Pak J Pharm Sci; 2008 Oct; 21(4):407-10. PubMed ID: 18930863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe irritant contact dermatitis causing skin ulceration secondary to a testosterone patch.
    Lawrentschuk N; Fleshner N
    ScientificWorldJournal; 2009 May; 9():333-8. PubMed ID: 19468653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of cosmetic patches containing lactic and glycolic acids.
    Mahdavi H; Kermani Z; Faghihi G; Asilian A; Hamishehkar H; Jamshidi A
    Indian J Dermatol Venereol Leprol; 2006; 72(6):432-6. PubMed ID: 17179618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic delivery systems: a new approach to evaluate physical properties of transdermal delivery systems (TDS).
    Ehrlich A; Henkel-Ernst J; Schaefer A; Assmussen B; Lücker PW
    Methods Find Exp Clin Pharmacol; 1999; 21(1):69-71. PubMed ID: 10222451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connubial androgenetic alopecia.
    Lattouf C; Miteva M; Tosti A
    Arch Dermatol; 2011 Nov; 147(11):1329-30. PubMed ID: 22106127
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma buprenorphine concentrations after the application of a 70 microg/h transdermal patch in dogs. Preliminary report.
    Andaluz A; Moll X; Ventura R; Abellán R; Fresno L; García F
    J Vet Pharmacol Ther; 2009 Oct; 32(5):503-5. PubMed ID: 19754919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of monolithic matrix patch system containing tulobuterol.
    Rhee YS; Kwon SY; Park CW; Choi NY; Byun WJ; Chi SC; Park ES
    Arch Pharm Res; 2008 Aug; 31(8):1029-34. PubMed ID: 18787793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.